24752-66-7

Upstream product

• 7623-09-8 2-chloropropionyl chloride 
• 100-46-9 benzylamine 
• 535-13-7 2-chloro-propanoic acid, ethyl ester 
• 27816-36-0 2-Chloropropionamide 
• 598-78-7 (R,S)-2-chloropropionic acid 

Downstream Products

• 79658-55-2 3-benzyl-5-methyl-1,3-oxazolidine-2,4-dione 
• 936908-14-4 N-benzyl-2-(n-butylthio)propanamide 
• 333454-24-3 N-4'-methylphenyl-2-(benzylthio)propanamide 
• 162375-38-4 N-benzyl-2-(phenylthio)propanamide 
• 936908-13-3 N-benzyl-Z-3-chloro-2-(n-butylthio)propenamide 
• 936908-17-7 N-benzyl-Z-3-chloro-2-(4'-methoxybenzenethio)propenamide 
• 936908-65-5 N-benzyl-(Z)-3-chloro-2-(benzylthio)propenamide 
• 162375-30-6 N-benzyl-Z-3-chloro-2-(phenylthio)propenamide 
• 482637-74-1 N-benzyl-2-(4-phenyl-5-(pyridin-3-yl)-4H-1,2,4-triazol-3-ylthio)acetamide 
• 10264-12-7 N-benzylpropanamide 

Relevant academic research and scientific papers

Atom-economic amide synthesis by using an iron-substituted polyoxometalate catalyst

We report an efficient and economical amidation strategy by using a polyoxometalate-based iron catalyst that affords the corresponding amide products in good yields. All of the aliphatic, aromatic and heterocyclic substrates are produced in high yields without additional base or organic ligands. Most importantly, the first example of heterogeneous iron(iii)-catalyzed formation of the diamides is developed.

Optimization of bifunctional piperidinamide derivatives as σ1R Antagonists/MOR agonists for treating neuropathic pain

Here, we describe the optimization, synthesis, and associated pharmacological analgesic activities of a new series of bifunctional piperidinamide derivatives as sigma-1 receptor (σ1R) antagonists and mu opioid receptor (MOR) agonists. The new compounds were evaluated in vitro in σ1R and MOR binding assays. The most promising compound 114 (also called HKC-126), showed superior affinities for σ1R and MOR and good selectivity to additional receptors related to pain. Compound 114 showed powerful dose-dependent analgesic effects in the acetic acid writhing test, formalin test, hot plate test, and chronic constriction injury (CCI) neuropathic pain model. In contrast to an equianalgesic dose of fentanyl, compound 114 produced fewer opioid-like side effects, such as reward liability, respiratory depression, physical dependence, and sedation. Lastly, the pharmacokinetic properties of this drug were also acceptable, and these results suggest that compound 114, as a mixed σ1R/MOR ligand, has potential for treating neuropathic pain.

Regioselective Thermal [3+2]-Dipolar Cycloadditions of α-Diazoacetates with α-Sulfenyl/Sulfinyl/Sulfonyl-β-Chloroacrylamide Derivatives to Form Densely Functionalised Pyrazoles

Highly regioselective synthetic methodology leading to densely functionalised C(3), C(4) and C(5) substituted pyrazoles 10a–q, 14a-i and 16a–g via thermal [3+2]-dipolar cycloaddition, of α-diazoacetates and α-thio-β-chloroacrylamides, at the sulfide, sulfoxide and sulfone levels of oxidation, is described. This method allows access to C(4)-sulfenyl or sulfonyl pyrazoles, through migration of the sulfur substituent at the sulfide and sulfone oxidation levels, while elimination of the sulfinyl group leading to 3,5-disubstituted pyrazoles, is observed. While the sulfide migration is readily rationalised, the carbon to carbon 1,2-sulfonyl migration is unprecedented and mechanistically intriguing. The synthetically versatile generation of densely functionalised pyrazoles containing substituents amenable to further modification offers advantages over alternative synthetic routes. Isolation of the N-alkylated pyrazoles 11a and 12a as by-products from the cycloaddition through further reaction of the pyrazoles 10 with excess α-diazoacetate, proved useful in rationalising the tautomeric behaviour evident in the NMR spectra of the pyrazoles, with the position of tautomeric equilibrium influenced by solvent and substituents.

Inhibitory Effects of New Mercapto Xanthine Derivatives in Human mcf7 and k562 Cancer Cell Lines

A series of new 2-methyl-2-[(1,3-Diethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)thio]-N- substituted arylacetamides were synthesized. The antitumor activity of these purine based compounds were evaluated on breast cancer (MCF7) and leukemic cancer (K562) cell lines via cell viability assay utilizing the tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). These results were substantiated using computer docking experiments (LigandFit docking engine and PMF scoring function) which predict that the antitumor activity of these new compounds may be attributable to their abilities to effectively bind and block oncogenic tyrosine kinases, particularly bcr/abl.

Design, synthesis and biological evaluation of novel dicarbonylalkyl piperazine derivatives as neuroprotective agents

In the search of novel neuroprotective agents with higher potency than our previously identified anti-ischemic stroke drug candidate 1, a series of novel dicarbonyl piperazine derivatives were synthesized and evaluated on their neuroprotective activity via oxygen-glucose deprivation test in the neuron-like PC12 cells, hypoxia tolerance model in mice and focal cerebral ischemia model in rats. The result obtained indicated that compounds 7f, 7k and 7o, exhibited neuroprotective activity. Particularly, compound 7o containing 2,5-dimethylpiperazin moiety, showed prolonged life time of mice and reduced cerebral infarction of rats, which provided a potential candidate for the development of neuroprotective agents.

In silico and experimental identification of non ulcerogenic antiinflammatory agents: 3-Thio substituted-4,5-diaryl-4H-1,2,4-triazoles

A new series of 4,5 diaryl-1,2,4-triazole-3-thione substituted carboxamides have been designed, synthesized and tested for their analgesic and antiinflammatory potential. All the tested compounds exhibit antiinflammatory activity comparable to that of standard drugs rofecoxib and diclofenac. Some compounds demonstrate significant analgesic activity in contrast to reference drugs. Compound 9c has emerged as a highly potent lead compound. Ulcerogenic studies of synthesized compounds and rofecoxib show nil or negligible ulcerogenic effect compared to diclofenac. In silico analysis (docking studies) of the most active compound 9c has revealed hypothetical binding mode of the target compound to the cyclooxygenase isoenzyme (COX-2). Docking study has anticipated stereoselective binding mode for the most active compound 9c.

Transamidation of primary amides with amines catalyzed by zirconocene dichloride

Zirconocene dichloride (Cp2ZrCl2) has been shown to be an effective catalyst for the transamidation of primary amides with amines in cyclohexane at 80°C in 5-24 hours. For favourable substrates, the reaction can be performed at temperatures as low as 30°C.

Transamidation of primary amides with amines catalyzed by zirconocene dichloride

Zirconocene dichloride (Cp2ZrCl2) has been shown to be an effective catalyst for the transamidation of primary amides with amines in cyclohexane at 80°C in 5-24 hours. For favourable substrates, the reaction can be performed at temperatures as low as 30°C.

Investigation of the synthetic and mechanistic aspects of the highly stereoselective transformation of α-thioamides to α-thio-β- chloroacrylamides

Treatment of a series of α-thioamides with N-chlorosuccinimide results in efficient transformation to the analogous α-thio-β- chloroacrylamides. The mechanistic pathway has been established through isolation and characterisation of intermediate compounds. The scope of the transformation has been explored - aryl and alkylthio substituents, primary, secondary and tertiary amides can be employed. In most instances, the chloroacrylamides are formed exclusively as the Z-stereoisomer; however, with tertiary propanamides or with amides derived from butanoic or pentanoic acid a mixture of E- and Z-stereoisomers is formed. The Royal Society of Chemistry.

One-pot synthesis of pyridazino[1,4]oxazin-3-ones

Pyridazino[1,4]oxazin-3-ones were conveniently prepared in a one-pot condensation of N-substituted 2-chloroacetamides with various 5-chloro-pyridazin-6-ones via rearrangement of a spiro-aminoketal intermediate.